search
Back to results

Treatment of Breast Fibroadenoma Targeted Tissue With HIFU (HIFU-003)

Primary Purpose

Breast Fibroadenoma

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ECHOPULSE
Sponsored by
Theraclion
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Fibroadenoma focused on measuring HIFU

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Female patients 18 years or older diagnosed with breast fibroadenoma and presenting at least one fibroadenoma.
  2. Diagnosis of fibroadenoma must be based on:

    1. Clinical examination
    2. Ultrasound image alone for patients under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. The BI-RADS score of this mammogram must be 2 or 3. BI-RADS score of 4 is eligible if biopsy indicates fibroadenoma with concordance.
    3. Histologic confirmation by core needle biopsy.
  3. Patient is a candidate for the surgery.
  4. The fibroadenoma treatment volume must be at least 5 mm and no more than 26 mm from the skin. This criterion should be evaluated immediately prior treatment, once the breast is immobilized and potentially compressed.
  5. The rib cage should not be in the prefocal ultrasound path or behind the target fibroadenoma (minimum distance from the posterior wall of the fibroadenoma must be at least 10 mm). This criterion shall be evaluated immediately prior to treatment, once breast is immobilized and potentially compressed.
  6. The fibroadenoma is 1 cm or greater at its largest dimension and no less than 7.5 mm in the anterior-posterior dimension (measured by ultrasound). Focal point for HIFU treatment must also be at least 3 mm from any border of the fibroadenoma.
  7. Patient's fibroadenoma size is greater or equal to 0.2 cc and less than 10 cc in volume (measured by ultrasound on the day of the procedure).
  8. Fibroadenoma is palpable.
  9. Pain ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days
  10. Anxiety ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days
  11. Patient has signed a written informed consent.

Exclusion Criteria:

  1. Patient is pregnant or nursing.
  2. Presence of calcified fibroadenoma. Calcification will be determined with mammography. In women > 35 years old, the diagnostic mammogram should be evaluated for calcification. In women ≤ 35 years old, a single view mammogram of the affected breast is sufficient for evaluation of calcification. Women ≤ 35 years old will be excluded based on the findings of calcification on a single view mammogram.
  3. Patient with history of breast cancer or history of laser or radiation therapy to the target breast.
  4. Patient with breast implants in the target breast.
  5. Patient with a breast cyst within the fibroadenoma to be treated.
  6. Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit.
  7. Patient participating in another clinical trial involving an investigational drug, device or biologic.

Sites / Locations

  • Bellevue Hospital CenterRecruiting
  • New York Columbia University Medical CenterRecruiting
  • Montefiore-Einstein Center for Cancer Care
  • University of Virginia Health systemRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ECHOPULSE

Arm Description

ECHOPULSE HIFU

Outcomes

Primary Outcome Measures

Pain level assessment
visual analog scale
Anxiety level assessment
visual analog scale
Volume assessment
Ultrasound measurement

Secondary Outcome Measures

The short (6-item) version of the State-Trait Anxiety Inventory (STAI)
Palpability of the breast fibroadenoma
Physician clinical examination
Freedom from additional procedures for fibroadenoma of the breast
Physician assessment concerning the need of additional procedures
Patient satisfaction
Self assessment satisfaction questionnaire
Safety endpoints include adverse events (AEs) and serious adverse events (SAEs) occurring at any time during the trial.
Assessment and capture of adverse events

Full Information

First Posted
January 17, 2017
Last Updated
October 18, 2022
Sponsor
Theraclion
search

1. Study Identification

Unique Protocol Identification Number
NCT03044054
Brief Title
Treatment of Breast Fibroadenoma Targeted Tissue With HIFU
Acronym
HIFU-003
Official Title
Treatment of Breast Fibroadenoma Targeted Tissue With High Intensity Focused Ultrasound (HIFU)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 2017 (undefined)
Primary Completion Date
August 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theraclion

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the efficacy and the safety of the HIFU for the treatment of breast fibroadenoma.
Detailed Description
Echopulse is specially designed, manufactured and CE marked for treating breast fibroadenoma. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to 85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted area.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Fibroadenoma
Keywords
HIFU

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ECHOPULSE
Arm Type
Experimental
Arm Description
ECHOPULSE HIFU
Intervention Type
Device
Intervention Name(s)
ECHOPULSE
Intervention Description
HIFU Under ultrasound guidance
Primary Outcome Measure Information:
Title
Pain level assessment
Description
visual analog scale
Time Frame
12 Months
Title
Anxiety level assessment
Description
visual analog scale
Time Frame
12 Months
Title
Volume assessment
Description
Ultrasound measurement
Time Frame
12 Months
Secondary Outcome Measure Information:
Title
The short (6-item) version of the State-Trait Anxiety Inventory (STAI)
Time Frame
inclusion visit (V0), Day 2/3, Day 7, 6 months, 12 months
Title
Palpability of the breast fibroadenoma
Description
Physician clinical examination
Time Frame
inclusion visit (V0), Day 2/3, Day 7, 6 months, 12 months
Title
Freedom from additional procedures for fibroadenoma of the breast
Description
Physician assessment concerning the need of additional procedures
Time Frame
Day 2/3, Day 7, 6 months, 12 months
Title
Patient satisfaction
Description
Self assessment satisfaction questionnaire
Time Frame
Month 6 and Months 12
Title
Safety endpoints include adverse events (AEs) and serious adverse events (SAEs) occurring at any time during the trial.
Description
Assessment and capture of adverse events
Time Frame
Day 0, Day 2/3, Day 7, 6 months, 12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients 18 years or older diagnosed with breast fibroadenoma and presenting at least one fibroadenoma. Diagnosis of fibroadenoma must be based on: Clinical examination Ultrasound image alone for patients under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. The BI-RADS score of this mammogram must be 2 or 3. BI-RADS score of 4 is eligible if biopsy indicates fibroadenoma with concordance. Histologic confirmation by core needle biopsy. Patient is a candidate for the surgery. The fibroadenoma treatment volume must be at least 5 mm and no more than 26 mm from the skin. This criterion should be evaluated immediately prior treatment, once the breast is immobilized and potentially compressed. The rib cage should not be in the prefocal ultrasound path or behind the target fibroadenoma (minimum distance from the posterior wall of the fibroadenoma must be at least 10 mm). This criterion shall be evaluated immediately prior to treatment, once breast is immobilized and potentially compressed. The fibroadenoma is 1 cm or greater at its largest dimension and no less than 7.5 mm in the anterior-posterior dimension (measured by ultrasound). Focal point for HIFU treatment must also be at least 3 mm from any border of the fibroadenoma. Patient's fibroadenoma size is greater or equal to 0.2 cc and less than 10 cc in volume (measured by ultrasound on the day of the procedure). Fibroadenoma is palpable. Pain ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days Anxiety ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days Patient has signed a written informed consent. Exclusion Criteria: Patient is pregnant or nursing. Presence of calcified fibroadenoma. Calcification will be determined with mammography. In women > 35 years old, the diagnostic mammogram should be evaluated for calcification. In women ≤ 35 years old, a single view mammogram of the affected breast is sufficient for evaluation of calcification. Women ≤ 35 years old will be excluded based on the findings of calcification on a single view mammogram. Patient with history of breast cancer or history of laser or radiation therapy to the target breast. Patient with breast implants in the target breast. Patient with a breast cyst within the fibroadenoma to be treated. Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit. Patient participating in another clinical trial involving an investigational drug, device or biologic.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michel NUTA, MD
Phone
633404004
Email
michel.nuta@theraclion.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michel NUTA, MD
Organizational Affiliation
Theraclion
Official's Role
Study Director
Facility Information:
Facility Name
Bellevue Hospital Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jocelyn Acosta
First Name & Middle Initial & Last Name & Degree
Kathie-Ann Joseph, Prof
First Name & Middle Initial & Last Name & Degree
Chloe Chhor, Dr
First Name & Middle Initial & Last Name & Degree
Shubhada Dhage, Dr
Facility Name
New York Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Alonso
First Name & Middle Initial & Last Name & Degree
Margaret Chen-Seetoo, Dr
Facility Name
Montefiore-Einstein Center for Cancer Care
City
New York
State/Province
New York
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Prena Etchen
First Name & Middle Initial & Last Name & Degree
REIG Beatriu, MD
Facility Name
University of Virginia Health system
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katie Rea
First Name & Middle Initial & Last Name & Degree
David Brenin, Prof
First Name & Middle Initial & Last Name & Degree
Carrie Rochmann, Dr
First Name & Middle Initial & Last Name & Degree
Jonathon Nguyen, Dr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Treatment of Breast Fibroadenoma Targeted Tissue With HIFU

We'll reach out to this number within 24 hrs